Tesamorelin

Tesamorelin is a synthetic analog of GHRH, FDA-approved for reducing visceral fat in HIV-associated lipodystrophy. It stimulates endogenous GH secretion, leading to significant reductions in visceral adipose tissue (VAT) and improvements in body composition. Outside this use, it has been studied in research settings for its effects on growth hormone release, body composition, and metabolic function. In research settings when stacked with Ipamorelin or GHRP-based peptides, it creates sustained GH elevation with improved metabolic outcomes.

• Stimulates the pituitary gland to increase growth hormone secretion, which in turn affects adipose tissue metabolism, particularly reducing visceral fat.

• unit: mg

  low dose: 2

  frequency: daily

  high dose: 2

  standard dose: 2

  administration route: Subcutaneous (SQ)

• Administer 2 mg SubQ once daily for up to 60 days. Typical off-label use includes 4–6 weeks on, followed by a 2–4 week break. Can be combined with Ipamorelin or CJC-1295 for amplified GH response. Monitor IGF-1 levels and glucose tolerance during extended use.

common: ["Joint pain (arthralgia), muscle aches, peripheral edema","Carpal tunnel symptoms (dose-dependent, reversible)","IGF-1 elevation requires monitoring; small HbA1c increases observed"]

warnings: ["Contraindicated in active malignancies, pregnancy, hypersensitivity to tesamorelin/mannitol"]

sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Ser-Ser-Val-Leu-Ser-Ser-Leu-Leu-Gln-Glu-Glu-Ala-Val-Lys-Glu-Arg-Asp-Glu-Ile-NH2

half life: Approximately 26 minutes

degradation: Metabolized primarily in the liver.

molecular weight: 5135.8

molecular formula: C221H366N72O67S

tissue specificity: Targets abdominal adipose tissue to reduce fat.

• Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.reviewPMID 22298602 ↗
• Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.reviewPMID 21668043 ↗